#41 Cracking the genetic code of complex chronic illness with Steve Gardiner, PrecisionLife

PrecisionLife are cracking the genetic code in complex chronic illness with their latest research in ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome) and Long Covid. Through large-scale studies in with DecodeME, the LOCOME Project, Sano Genetics' Gold dataset, and the All of Us research programme, they have identified hundreds of genes associated with Long COVID and ME/CFS.  They believe this genetic data reveals the different patient phenotypes within these conditions, and how each might be treated. This week, PrecisionLife's CEO Steve Gardner shares the work that they have been doing. He discusses why these findings mark a transformational point in our understanding, diagnosis, and treatment of complex chronic illness. He explains: What they have identified in the genetics of ME/CFS and Long COVID patients The implications of the genetic overlaps and differences between the two conditions Why stratification is essential in clinical trial design and treatment How this genetic understanding could shape targeted treatment The 42 repurposed drug candidates that they have identified so far Steve Gardner believes this work has created a profound shift in our understanding of ME/CFS, Long COVID and has potential across many complex chronic conditions. Collaborating with key organisations including the Complex Disorders Alliance (CODA), Action for ME, Innovate UK, and the Metrodora Institute, PrecisionLife is using precision medicine to individualise treatment and build new pipelines and pathways for ME/CFS and Long COVID patients.   View PrecisionLife’s work into Long Covid and ME/CFS here. Complete the survey to register your interest in Post COVID DNA Wellness Report here. View the Patient Recap of the ISLC-PAIS Conference here.   Interested in taking part or sharing feedback on Make Visible?  Please click here. Make Visible @visible.health podfeedback@makevisible.com